Analysts at StockNews.com started coverage on shares of AC Immune (NASDAQ:ACIU – Get Free Report) in a research note issued to investors on Thursday. The brokerage set a “sell” rating on the stock.
Separately, HC Wainwright restated a “buy” rating and issued a $16.00 target price on shares of AC Immune in a research note on Monday, August 7th.
View Our Latest Stock Report on AC Immune
AC Immune Stock Performance
AC Immune (NASDAQ:ACIU – Get Free Report) last released its quarterly earnings data on Friday, August 4th. The company reported ($0.22) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.22). On average, analysts forecast that AC Immune will post -0.71 earnings per share for the current fiscal year.
Institutional Investors Weigh In On AC Immune
Several institutional investors have recently bought and sold shares of the company. Citigroup Inc. purchased a new position in shares of AC Immune in the first quarter worth $2,036,000. Avidity Partners Management LP raised its holdings in shares of AC Immune by 18.4% in the fourth quarter. Avidity Partners Management LP now owns 325,400 shares of the company’s stock worth $664,000 after buying an additional 50,524 shares during the last quarter. Banque Cantonale Vaudoise raised its holdings in shares of AC Immune by 54.9% in the first quarter. Banque Cantonale Vaudoise now owns 65,803 shares of the company’s stock worth $154,000 after buying an additional 23,315 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of AC Immune by 1.6% in the first quarter. Renaissance Technologies LLC now owns 411,079 shares of the company’s stock worth $962,000 after buying an additional 6,400 shares during the last quarter. Finally, Millennium Management LLC purchased a new position in shares of AC Immune in the fourth quarter worth $222,000. 19.17% of the stock is currently owned by institutional investors and hedge funds.
About AC Immune
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Recommended Stories
- Five stocks we like better than AC Immune
- How to Invest in Casino Stocks
- Huawei Has Entered The Chips Race, Markets Still Prefer These
- How to Invest in the Healthcare Sector
- Restaurant Stocks Go on Sale…Which Are Really on the Value Menu?
- Stock Market Upgrades: What Are They?
- 5 Reasons to Buy and Hold Exxon Mobil For 2024
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.
